RareStone Inc. Announces Submission of New Drug Application (NDA) of Wakix® (pitolisant) for narcolepsy with and without cataplexy in China
Wakixwill be considered for approval in the treatment of narcolepsy with and without cataplexy in Greater China.
- Wakixwill be considered for approval in the treatment of narcolepsy with and without cataplexy in Greater China.
- Through a partnership announced in Q4 2020 with Bioprojet, RareStone has exclusive rights for the commercialization and development of Wakixin China.
- RareStone's lead product candidate, Wakix (pitolisant), is an investigational oral drug in development for the treatment of narcolepsy and obstructive sleep apnea in China.
- Pitolisant has an orphan designation in the EU and the US for the treatment of narcolepsy.